Dysport (AbobotulinumToxin), a form of purified botulinum toxin, has been granted a positive review in Europe for treating urinary incontinence in adults with neurogenic detrusor hyperactivity (NDO). Studies have shown that Dysport, injected into the detrusor muscle, reduces urinary incontinence due to NDO in patients with multiple sclerosis or spinal cord injury. This survey was part of the EU botulinum toxin risk management plan to identify the possible educational needs of people who inject injections by collecting data on the routine administration of Dysport in their usual practices and their knowledge of possible adverse events (AEs) that are included in the current product label. The participants were randomly assigned to receive one of two doses of Dysport of 600 or 800 units or a placebo, injected into the detrusor muscle. After six weeks, patients who received the placebo had a 12.7% reduction in their average number of weekly episodes, compared to an average reduction of more than 22 episodes per week in the Dysport groups.
More than 60% of patients treated with Dysport had an increase of 11 points or more in their I-QOL scores after six weeks, compared to 32% in the placebo group. Dysport also significantly increased the volume of urine per vacuum, by more than 80 ml over the six weeks, compared to a reduction of 5.9 ml per vacuum in the placebo group. Dysport (Ipsen Ltd, Wrexham, United Kingdom) is a botulinum neurotoxin type A preparation that has been available for various therapeutic uses for more than 20 years in the European Union (EU). The detailed recommendations for the use of Dysport are described in the Summary of Product Characteristics (SmPC) for Dysport (300 units) in powder and Dysport (500 units) in powder, and the U. S.
Food and Drug Administration approved labeling for Dysport. More than 40% of patients in the active group received no additional treatment with Dysport, meaning that their benefits were derived from a single injection. Dysport is a form of botulinum toxin type A approved in multiple sclerosis to relieve abnormal muscle stiffness (spasticity) in the upper and lower limbs. With this opinion, European Union countries can now grant marketing approval to Dysport at the national level. Dysport is an effective treatment option for those suffering from urinary incontinence due to NDO or overactive bladder.
It has been approved by the European Union and has been used safely and effectively for more than 20 years. It is important to note that while Dysport is an effective treatment option, it is not suitable for everyone and should be used only under medical supervision.
